Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TERN 701

Next Previous
Drug Profile

TERN 701

Alternative Names: HS-10382; TERN-701; TRN-000632

Latest Information Update: 23 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Terns Pharmaceuticals
  • Developer Jiangsu Hansoh Pharmaceutical; Terns Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Chronic myeloid leukaemia

Most Recent Events

  • 08 Jan 2026 Phase-I/II clinical trials in Chronic myeloid leukaemia (Second-line therapy or greater) in Australia (PO)
  • 08 Jan 2026 Phase-I/II clinical trials in Chronic myeloid leukaemia (Second-line therapy or greater) in South Korea, USA, France, Spain, Italy, Germany, United Kingdom and New Zealand (PO) (NCT06163430)
  • 08 Jan 2026 Terns Pharmaceuticals plans receives End of Phase 2 regulatory interaction with US FDA for TERN 701 in Chronic myeloid leukemia in mid-2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top